全球前葡萄膜炎治療市場規模、佔有率和成長分析：按治療和分銷管道 - 行業預測（2024-2031）

2022年全球前葡萄膜炎治療市場規模將為3.5億美元，從2023年的3710億美元成長到2031年的5913.2億美元，在預測期內（2024年-2031年）預計複合年成長率為6 %。

傳播的一個主要促進因素是前葡萄膜炎病例的迅速增加，其特徵是眼睛葡萄膜前部的發炎。治療主要涉及皮質類固醇和免疫抑制劑，通常是皮質類固醇眼藥水。多種潛在疾病可誘發前​​葡萄膜炎並導致其流行。皮質類固醇的處方取決於葡萄膜炎的類型，因為它們會影響免疫系統。隨著世界老化，這種疾病的脆弱性增加。以修美樂 (Humira)的核准為代表的治療方法創新，以及意識提高、眼部感染率和有利的法規環境等因素，預計將推動成長。與前葡萄膜炎相關的併發症包括眼壓升高和皮質類固醇治療的潛在副作用，導致青光眼和白內障等疾病，因此沒有有效的治療方法來預防不可逆轉的視力喪失，這凸顯了有效管理策略的必要性。

目錄

執行摘要

• 市場概況
• 命運之輪

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模估算
• 市場假設與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管環境
• 波特的分析
• 對未來中斷的特殊考慮

前葡萄膜炎治療的全球市場：依治療分類

• 市場概況
• 皮質類固醇
• 循環麻木劑
• 抗TNF劑
• 免疫抑制劑

全球前葡萄膜炎治療市場：按分銷管道

• 市場概況
• 醫院
• 零售
• 網路藥房

全球前葡萄膜炎治療市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2021年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2021年）

主要企業簡介

• Novartis AG
• Allergan（now part of AbbVie Inc.）
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Alcon Inc.
• EyePoint Pharmaceuticals
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International（now Bausch Health Companies Inc.）
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• AbbVie Inc.
• Bausch Health Companies Inc.
• Mylan NV
• Akorn Pharmaceuticals
• Ocular Therapeutix, Inc.
• Clearside Biomedical, Inc.
• Topcon Corporation
• Carl Zeiss Meditec AG

Global Anterior Uveitis Treatment Market size was valued at USD 350 million in 2022 and is poised to grow from USD 371 billion in 2023 to USD 591.32 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The surge in cases of anterior uveitis is a significant driving force behind its expansion, characterized by inflammation in the front portion of the eye's uvea. Management primarily involves corticosteroids and immunosuppressive agents, often administered through corticosteroid eye drops. Various underlying conditions can trigger anterior uveitis, contributing to its prevalence. Prescription of corticosteroids is contingent upon the type of uveitis due to their impact on the immune system. With an aging global population, the vulnerability to this condition increases. Innovations in treatments, exemplified by Humira's approval, are expected to fuel growth, alongside factors such as heightened awareness, ocular infection rates, and favorable regulatory environments. Complications associated with anterior uveitis include elevated intraocular pressure and potential adverse reactions to corticosteroid treatment, leading to conditions like glaucoma and cataracts, emphasizing the need for effective management strategies to prevent irreversible blindness.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anterior Uveitis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anterior Uveitis Treatment Market Segmental Analysis

The global anterior uveitis treatment market is segmented on the basis of treatment, distribution channel, region. By treatment, the market is segmented into corticosteroids, cycloplegic agents, anti-tnf agents, immunosuppressants. By distribution channel, the market is segmented into hospital, retail, online pharmacies. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Anterior Uveitis Treatment Market

The rising prevalence of anterior uveitis worldwide, along with the expanding elderly population, serves as a key factor propelling market growth. With the disease becoming more widespread, there is a heightened demand for efficient treatment options.

Restraints in the Global Anterior Uveitis Treatment Market

Certain treatment methods, notably corticosteroids, have the potential to induce undesirable outcomes such as elevated intraocular pressure, cataracts, and glaucoma, which can constrain their prolonged application and impact patient adherence.

Market Trends of the Global Anterior Uveitis Treatment Market

Exploring gene therapies offers hope in tackling the underlying triggers of anterior uveitis through the precise targeting of particular genetic mutations or irregularities linked to this condition.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Anterior Uveitis Treatment Market by Treatment

• Market Overview
• Corticosteroids
• Cycloplegic Agents
• Anti-TNF Agents
• Immunosuppressants

Global Anterior Uveitis Treatment Market by Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Global Anterior Uveitis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (now part of AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (now Bausch Health Companies Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments